Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The user has been using topical finasteride and minoxidil foam for 6 months and is satisfied with the fuller appearance of their hair. They are considering switching to topical dutasteride but cannot find it in Canada.

New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.

Diffuse thinning can result in varied regrowth, with some users experiencing better results at the hairline and others at the crown. Treatments mentioned include finasteride, minoxidil (oral and topical), RU58841, microneedling, and dermarolling.

Amplifica has not provided updates on SCUBE3 and AMP-303, raising concerns about their trial outcomes. Users also mention other treatments like Minoxidil, finasteride, RU58841, PP405, and ET-03.

The user is using Minoxidil, Finasteride, Nizoral, Nutrafol supplements, and PRP sessions for hair loss treatment. They are concerned about the effectiveness of these treatments and whether they should continue or consider a hair transplant.

PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.

The conversation discusses using Rogain foam as a solvent for topical finasteride due to an allergy to propylene glycol. The foam's ingredients, including alcohol SD 40B, are considered suitable for dissolving finasteride for easier application without skin irritation.

The conversation discusses experiences with Haircross Hair Growth Serum, which contains Redensyl, Capixyl, Procapil, Anagain, and Baicapil, as an alternative to Minoxidil and Finasteride. Users report mixed results, with some experiencing no regrowth and others noting slight thickening, but concerns about side effects and effectiveness compared to standard treatments remain.

The conversation discusses potential hair loss treatments, including clascoterone, GT20029, ET-02, VDPHL01, and PP405, with hopes for new options by 2028. Current treatments like minoxidil and finasteride are expected to remain effective, with clascoterone and VDPHL01 as promising alternatives.

RU58841, Minoxidil, and finasteride are discussed as treatments for hair loss. RU58841 is highlighted for its potential effectiveness.

The conversation discusses Dr. Blake Bloxham's experiment with Verteporfin for hair loss, with one person suggesting more doctors should try it as it seems beneficial. Another comment notes that results at 4-5 months were not very impressive.

A user is seeking a specialized clinic in Montreal for a thorough hair loss diagnosis and personalized treatment plan. A recommendation for Rico Clinic is provided.

DLQ01, a prostaglandin F2α analog, shows promise for hair growth by directly stimulating PGE2/PGF receptors without needing conversion, and can be combined with minoxidil and retinoids like tretinoin for enhanced effectiveness. Minoxidil's efficacy may be reduced by COX-1 inhibitors, but using prostaglandin analogs like Latanoprost or Bimatoprost can help maintain its effectiveness.

The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.

Redensyl, Capixyl, and Procapil combined are compared to 5% Minoxidil for treating hair loss. The discussion focuses on the effectiveness of these treatments.

The user experienced significant hairline improvement after 2 months using 1 mg Finasteride and topical Minoxidil, with only initial shedding as a side effect. The progress is notable, with the user returning from near Norwood 2 to Norwood 1, and they use Rogaine for topical application.

The user experienced severe scalp itching after using RU58841 and ketoconazole shampoo, despite trying moisturizing treatments. They suspect the issue is related to the propylene glycol in the vehicle and are seeking alternatives.

Exploring the idea of using facial hair properties for scalp regeneration in male pattern baldness, considering the potential of transferring androgen-resistant characteristics from facial hair to the scalp. Challenges include complexity, scalability, aesthetics, and safety, but the concept encourages innovative thinking beyond current treatments like Minoxidil, Finasteride, and hair transplants.

The conversation discusses the lack of experiments combining verteporfin and microneedling for hair loss treatment. The user expresses interest in participating in a group buy to try this method.

Transplanting mice skin to humans is not feasible due to immune rejection, but some suggest genetic modification or immune suppression could make it possible. Xenograft hair transplants are discouraged.

Tretinoin may enhance the effectiveness of minoxidil for hair regrowth by increasing enzyme activity and skin permeability, but its standalone impact is limited. Some users experienced improved hair growth with tretinoin, while others found it worsened their condition.

Hair transplants can significantly enhance attractiveness and confidence, especially in dating, as many women value a good hairline. The original poster found finasteride ineffective and opted for a successful hair transplant, recommending it for those considering surgery.

The conversation discusses using minoxidil with retinol for hair loss treatment. Users share their experiences and opinions on the effectiveness of this combination.

The user shared progress pictures showing significant improvement in hair loss after using finasteride, RU58841, and undergoing a 3000 graft hair transplant. They plan to get another transplant due to remaining thin areas.

Microneedling can enhance hair growth by increasing drug absorption and activating stem cells, with different needle depths serving distinct purposes. Users report success with microneedling, often in combination with treatments like minoxidil and finasteride, and emphasize waiting periods for topical application to avoid side effects.

PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.

A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.

A recent discovery in hair cloning identified a previously unknown cell type essential for hair follicle growth, which could potentially make lab-grown hair viable if translated to humans. However, skepticism remains due to past delays and the challenges of replicating results in humans and making the process affordable.

Verteporfin is discussed as a potential treatment for scarring alopecia. Minoxidil is suggested as an alternative treatment.

A 27-year-old experienced significant hair regrowth after a hair transplant with 4349 grafts, supported by minoxidil and finasteride, improving his confidence. He plans to update on further progress at 9–12 months.